ISHL12 2022 | The challenges with treating high-risk patients with HL: a Brazilian perspective
Irene Biasoli
• 26 Oct 2022
Irene Biasoli, MD, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil, shares some insights into the challenges with treating high-risk patients with advanced-stage Hodgkin lymphoma (HL) in Brazil. Dr Biasoli highlights why clinicians most frequently use ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) as frontline treatment for HL patients, and further comments on the need to improve access to novel agents such as brentuximab vedotin. This interview took place at the 12th International Symposium on Hodgkin Lymphoma (ISHL12), held in Cologne, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
